We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...
Superpower, the company empowering members to take control of their health, today announces the launch of the world’s first health super-app—beginning with the most comprehensive biomarker testing ...
(Denver, Colo.—July 14, 2025) -- A multidisciplinary guideline panel convened by the American Association of Bronchology and Interventional Pulmonology (AABIP) and the Early Detection & Screening ...
Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...
Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer Patients with treatment-naïve aNSCLC were tested ...
CHICAGO, Nov. 19, 2024 /PRNewswire/ -- Lung cancer is the leading cause of the cancer deaths in the U.S., but the American Lung Association's 2024 "State of Lung Cancer" report reveals positive news.
Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...
Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. • HIMS stock is racing ...
Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈